Recombinant Human AIDA, His-tagged
Cat.No. : | AIDA-7533H |
Product Overview : | Recombinant human AIDA protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques. |
- Specification
- Gene Information
- Related Products
Antigen Description : | AIDA acts as a ventralizing factor during embryogenesis. This protein inhibits axin-mediated JNK activation by binding axin and disrupting axin homodimerization. This in turn antagonizes a Wnt/beta-catenin-independent dorsalization pathway activated by AXIN/JNK-signaling. |
Source : | E. coli |
Species : | Human |
Tag : | His |
Form : | Liquid. 20mM Tris-HCl buffer (pH8.0) containing 10% glycerol 0.2M NaCl,1mM DTT |
Molecular Mass : | 37.4kDa(329aa) confirmed by MALDI-TOF |
Protein length : | 1-306 aa |
AA Sequence : | MGSSHHHHHH SSGLVPRGSH MGSMSEVTRS LLQRWGASFR RGADFDSWGQ LVEAIDEYQI LARHLQKEAQ AQHNNSEFTE EQKKTIGKIA TCLELRSAAL QSTQSQEEFK LEDLKKLEPI LKNILTYNKE FPFDVQPVPL RRILAPGEEE NLEFEEDEEE GGAGAGSPDS FPARVPGTLL PRLPSEPGMT LLTIRIEKIG LKDAGQCIDP YITVSVKDLN GIDLTPVQDT PVASRKEDTY VHFNVDIELQ KHVEKLTKGA AIFFEFKHYK PKKRFTSTKC FAFMEMDEIK PGPIVIELYK KPTDFKRKKL QLLTKKPLYL HLHQTLHKE |
Purity : | >90% as determined by SDS - PAGE |
Applications : | SDS-PAGE |
Storage : | Can be stored at 4°C short term (1-2 weeks). For long term storage, aliquot and store at -20°C or -70°C.Avoid repeated freezing and thawing cycles. |
Concentration : | 0.25 mg/ml |
Gene Name : | AIDA axin interactor, dorsalization associated [ Homo sapiens ] |
Official Symbol : | AIDA |
Synonyms : | AIDA; axin interactor, dorsalization associated; C1orf80, chromosome 1 open reading frame 80; axin interactor, dorsalization-associated protein; axin interaction partner and dorsalization antagonist; FLJ12806; C1orf80; FLJ32421; RP11-378J18.7; |
Gene ID : | 64853 |
mRNA Refseq : | NM_022831 |
Protein Refseq : | NP_073742 |
MIM : | 612375 |
UniProt ID : | Q96BJ3 |
Chromosome Location : | 1q41 |
Function : | protein domain specific binding; |
Products Types
◆ Recombinant Protein | ||
Aida-393M | Recombinant Mouse Aida Protein, MYC/DDK-tagged | +Inquiry |
AIDA-4240H | Recombinant Human AIDA Protein, GST-tagged | +Inquiry |
AIDA-36C | Recombinant Cynomolgus Monkey AIDA Protein, His (Fc)-Avi-tagged | +Inquiry |
AIDA-410M | Recombinant Mouse AIDA Protein, His (Fc)-Avi-tagged | +Inquiry |
AIDA-1448M | Recombinant Mouse AIDA Protein | +Inquiry |
◆ Lysates | ||
AIDA-8957HCL | Recombinant Human AIDA 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (12)
Ask a questionDysregulation of AIDA expression has been implicated in several cancer types. In some cases, AIDA mutations or overexpression have been associated with increased genetic instability and mutations, which can contribute to tumor progression. In other cases, AIDA has been shown to promote oncogenic signaling pathways or suppress tumor suppressor genes, leading to uncontrolled cell growth. Additionally, AIDA expression in tumor cells can promote immune evasion and reduce the effectiveness of immunotherapies. Therefore, studying the role of AIDA in cancer is important for developing new cancer therapies and improving clinical outcomes.
The dysregulation of AIDA expression has been associated with several diseases, including cancer, autoimmune disorders, and infections. Therefore, AIDA protein levels or activity could be used as a diagnostic or prognostic biomarker for certain diseases. Additionally, AIDA-targeted therapies or drugs could be used as a treatment option for diseases with dysregulated AIDA expression. However, more research is needed to establish the clinical relevance of AIDA as a diagnostic tool and its potential for precision medicine.
Many techniques are used to study AIDA protein and its functions. These include genetic engineering approaches to manipulate AIDA expression or mutations in model systems, biochemical techniques such as protein purification and enzymatic assays to examine AIDA's enzymatic activity, and imaging methods such as fluorescence microscopy to visualize AIDA localization and dynamics. In recent years, advances in genome editing technologies such as CRISPR-Cas9 have made it possible to study the role of AIDA in B cells and other systems with greater precision and efficiency.
One major challenge in targeting AIDA is the potential for off-target effects. Because AIDA is involved in a variety of cellular processes beyond immunoglobulin diversification, inhibiting or altering its activity has the potential to affect many other cellular systems. This presents a risk of unwanted side effects, such as increased susceptibility to infections or enhanced genetic instability. Another challenge is the potential for the development of resistance to AIDA-targeted therapies, similar to the resistance seen with other cancer therapies. Additionally, improving the selectivity and efficacy of AIDA-targeted therapies requires a better understanding of how AIDA functions in different cellular contexts, which is still an active area of research.
While AIDA's primary function is to facilitate immunoglobulin diversification in B cells, it has been implicated in other cellular processes as well. For instance, AIDA has been reported to have a role in DNA repair mechanisms and genome stability through the regulation of non-homologous end joining (NHEJ) and homologous recombination (HR) pathways. It has also been suggested that AIDA could play a role in modulating cell signaling pathways and cellular responses to oxidative stress. However, these roles of AIDA are still being explored, and further research is needed to fully understand its functions beyond antibody diversification.
AIDA protein is not unique to humans; it is found in many mammalian species, including mice, rats, cows, and dogs. However, AIDA orthologs are not present in all species. For instance, AIDA has not been identified in zebrafish or fruit flies. The presence or absence of AIDA orthologs across species suggests that its role in immunoglobulin diversification may have evolved in a lineage-specific manner.
The expression of AIDA is regulated at multiple levels, including transcriptional and post-transcriptional mechanisms. Transcriptional regulation involves various factors that can activate or repress AIDA gene transcription, such as Myc and PU.1. Post-transcriptional mechanisms, such as microRNA-mediated regulation or RNA-binding protein interactions, can also influence AIDA expression by modulating mRNA stability or translation. AIDA protein stability is also regulated by post-translational modifications such as ubiquitination or sumoylation.
Given AIDA's crucial role in immunoglobulin diversification and potential involvement in cancer and other diseases, targeting AIDA has emerged as a potential therapeutic approach. One strategy is to inhibit AIDA's enzymatic activity, which could reduce genetic instability and reduce the risk of cancer development. Another approach is to target AIDA in B cells, which could be useful in treating certain autoimmune disorders such as lupus or rheumatoid arthritis. In addition, new immunotherapies that target AIDA or its downstream effects are under development, which could help enhance anti-tumor immune responses in cancer patients. Nevertheless, much more research is needed to explore and optimize these therapeutic options.
Yes, the dysregulation of the AIDA protein has been associated with several diseases, and targeting AIDA has shown promise in reducing disease severity or progression in preclinical models. However, developing effective AIDA-targeted therapies requires overcoming several challenges, such as ensuring specificity, avoiding off-target effects, and ensuring safety and tolerability.
AIDA dysregulation has been implicated in several diseases, including B-cell lymphomas, autoimmune diseases, and viral-associated cancers. In B-cell lymphomas, AIDA mutations or overexpression can lead to excessive somatic hypermutation and genetic instability, contributing to tumor growth. In autoimmune diseases, AIDA dysregulation can result in aberrant antibody production and tissue damage. Certain virus infections, such as hepatitis B and C viruses, can also induce AIDA expression and contribute to the development of virus-associated cancers.
AIDA has been explored as a potential tool for generating improved vaccine candidates. AIDA-mediated diversification of antibody repertoires can enable the production of high-affinity antibodies against vaccine targets. Additionally, AIDA has been used in "molecular breeding" strategies to introduce specific mutations or changes into vaccine antigens to enhance their effectiveness or broaden their coverage. However, such approaches require careful evaluation and optimization to avoid undesirable effects or safety concerns.
AIDA has been shown to play a role in shaping the gut microbiome through immunoglobulin diversification. AIDA-mediated antibody production can help maintain gut barrier integrity and regulate inflammation in response to microbiota-associated molecules. Dysregulation of AIDA expression in the gut has been linked to various gastrointestinal disorders, including inflammatory bowel disease and colorectal cancer.
Customer Reviews (4)
Write a reviewThey are highly knowledgeable and responsive, offering prompt solutions to any issues or concerns that may arise during my experiments.
The reliability of the protein and the continuous assistance from the manufacturer contribute significantly to the success and advancement of my research in immunology.
the high-quality AIDA protein and the excellent technical support provided by the manufacturer make it an ideal choice for my experimental endeavors.
Their expertise adds an extra layer of confidence to my research, knowing that I have a reliable resource to turn to when facing challenges.
Ask a Question for All AIDA Products
Required fields are marked with *
My Review for All AIDA Products
Required fields are marked with *
Inquiry Basket